Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer (vol 239, pg 39, 2016 )

© 2017 Elsevier B.V. The authors regret that a representative tumor photograph used in Fig. 4B (left) was published in parallel in another study (Grünwald et al., Mol Cancer Res. 2016 Nov; 14(11):1147–1158. doi:10.1158/1541-7786.MCR-16-0180, Epub 2016 Aug 3). The corrected Fig. 4B, containing another representative tumor photograph, appears below. The studies do not contain any overlapping experiments or conclusions. All conclusions drawn in either publication are correct and unaffected by the mistake. The authors apologize for the inconvenience caused.[figure presented] Corrected Fig. 4. Evaluation of MMP-9-dependent uptake of Magh@PNPs-PEG-RegaCP-PEG into pancreatic tumors in vivo. (A) Tumor-specific uptake of Magh@PNPs-PEG-RegaCP-PEG. Prussian Blue staining of PNPs in pancreatic tissue; arrows indicate nanomaterial. Tumor −, Healthy littermates (n = 5); Tumor +, KPC mice (n = 5); Representative images; bars, 100 μm. (B) MMP-9-deficient KPC mice were able to form pancreatic tumors. Left, Representative pancreas whole mount; bar, 1 cm; Right, HE staining of pancreatic sections; representative image; bar, 100 μm. (C) MMP-9- and tumor-dependent uptake of Magh@PNPs-PEG-RegaCP-PEG into pancreatic tissue as determined by Prussian Blue staining-based quantification. Tumor −, Healthy littermates; Tumor +, KPC mice; MMP9 +, wild-type mice; MMP9 −, MMP9 knock-out mice (n = 5 per group). Columns, mean; bars, SEM. One-way ANOVA: n.s., not significant; **p < 0.01; ***p < 0.001.status: publishe